245 filings
Page 8 of 13
424B3
m1pjzqhi2j
7 Nov 22
Prospectus supplement
6:26pm
DEFA14A
0gc bwnw8fl2kk46a4
7 Nov 22
Additional proxy soliciting materials
6:21pm
8-K
60i0ggrvb37 cci
7 Nov 22
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
6:21pm
8-K
6ggmhedd l1
14 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
6hqcnrs2g
11 Oct 22
Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
4:15pm
424B3
jefkwj2
7 Oct 22
Prospectus supplement
5:18pm
424B3
gva57btp 0f
30 Sep 22
Prospectus supplement
4:52pm
8-K
pziaaq jyj
30 Sep 22
Entry into a Material Definitive Agreement
4:49pm
DEFA14A
tmkm0 3ea5mtmjs8t
26 Sep 22
Additional proxy soliciting materials
4:36pm
424B3
b1fjg7hk3fvirlup2 8l
26 Sep 22
Prospectus supplement
4:34pm
8-K
2yxc1koqjld
26 Sep 22
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
4:30pm
DEFA14A
bqvo egx4pj4epcg
19 Sep 22
Additional proxy soliciting materials
5:00pm
DEF 14A
tks8ar9l70
19 Sep 22
Definitive proxy
4:34pm
8-K
llc1z6ho gu
12 Sep 22
Allarity Therapeutics Announces Appointment of New Auditor
4:10pm
PRE 14A
8w4vcg7ycgmmawe
8 Sep 22
Preliminary proxy
5:00pm
6-K
oqyj3vp8 oigaowpn2k
31 Aug 22
Report of Foreign Private Issuer
11:56am
8-K
nr9paw87w
29 Aug 22
Regulation FD Disclosure
6:30am
8-K
yfw958ap
26 Aug 22
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance
4:37pm
8-K/A
11iuc
24 Aug 22
Changes in Registrant's Certifying Accountant
5:15pm